Is Egrifta (Tesamorelin) Legal in Tennessee?

Federal Legal Status: The Foundation for Tennessee Access

Tesamorelin is an FDA-approved prescription drug, not a research chemical or gray-market peptide. That distinction matters enormously for anyone asking about legality.

The FDA granted approval on November 24, 2010, under NDA 022505 for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The approved brand is Egrifta SV, marketed by Theratechnologies. Because it holds full approval, it is not subject to the ambiguous "research chemical" rules that apply to unapproved peptides such as BPC-157 or CJC-1295.

Scheduling and Controlled-Substance Status

Tesamorelin does not appear on the DEA Schedule I through V list. The DEA Controlled Substances Act scheduling framework applies to compounds with abuse potential; tesamorelin does not meet that threshold. Prescribers do not need a DEA Form 222 or any special DEA registration to dispense or prescribe it beyond their standard practitioner registration.

How the FDA Approval Shapes Prescribing

FDA approval means a licensed physician may prescribe Egrifta for its labeled indication without restriction. The FDA also permits off-label prescribing at physician discretion, though insurance coverage for off-label use is rarely available. The FDA's guidance on off-label use confirms that prescribing outside the approved indication is a legal medical practice decision.

Tennessee State Law: What It Does (and Does Not) Add

Tennessee does not have a tesamorelin-specific statute. No state law singles out this peptide for restriction, prohibition, or special scheduling beyond what federal law already requires.

Tennessee Pharmacy Practice Act

The Tennessee Pharmacy Practice Act (Tenn. Code Ann. Title 63, Chapter 10) governs how pharmacies dispense prescription drugs. Under that framework, a pharmacist in Tennessee may dispense Egrifta when presented with a valid, signed prescription from a Tennessee-licensed (or reciprocally recognized) prescriber. No additional state permit is needed to stock or dispense an FDA-approved Schedule-exempt drug.

Tennessee Medical Practice Act

The Tennessee Medical Practice Act (Tenn. Code Ann. Title 63, Chapter 6) governs physician prescribing. A physician licensed by the Tennessee Board of Medical Examiners may prescribe tesamorelin for a patient with a qualifying diagnosis. The standard of care requirement, a legitimate patient-physician relationship, documented diagnosis, and individualized treatment plan, applies exactly as it does for any other prescription medication.

Telehealth Prescribing in Tennessee

Tennessee enacted the Telehealth Act (Tenn. Code Ann. § 56-7-1002) and follows the Interstate Medical Licensure Compact, which allows out-of-state physicians to hold a Tennessee license efficiently. A telehealth visit with a board-certified physician establishes the patient-physician relationship required by both Tennessee and federal law. The Tennessee Department of Health telehealth page confirms that telehealth prescribing for non-controlled prescription drugs is permitted when the standard of care is met.

The Clinical Evidence Behind the Prescription

Understanding why a physician would prescribe tesamorelin helps clarify what kind of consultation to expect.

LIPO-010 and LIPO-011 Trials

The FDA approval rests primarily on two Phase 3 randomized controlled trials. LIPO-010 and LIPO-011 enrolled a combined 816 HIV-infected adults with excess visceral adipose tissue (VAT). Participants received tesamorelin 2 mg subcutaneously once daily or placebo for 26 weeks. In the pooled analysis, tesamorelin reduced VAT by a mean of 15.2% versus a 4.8% increase in the placebo group (P<0.001) [1]. Quality-of-life scores related to body image also improved significantly in treated participants [1].

IGF-1 Elevation and Monitoring

Tesamorelin works by binding to growth-hormone-releasing hormone (GHRH) receptors on pituitary somatotrophs, stimulating pulsatile GH secretion and downstream IGF-1 production. The prescribing information for Egrifta SV states that IGF-1 levels should be monitored during treatment, with dose adjustment or discontinuation if levels exceed the age-normalized upper limit of normal. Glucose tolerance may also worsen because GH is counter-regulatory to insulin; fasting glucose and HbA1c monitoring are recommended at baseline and periodically during therapy [2].

Discontinuation Criteria

The prescribing information specifies a clear stopping rule: if a patient shows no reduction in VAT by ultrasound or CT assessment at week 26, the drug should be discontinued. This evidence-based decision point distinguishes tesamorelin from less-studied peptides that lack structured treatment endpoints.

Compounding: When a 503A or 503B Pharmacy Can Prepare Tesamorelin

Because Egrifta SV carries FDA approval, compounding tesamorelin occupies a narrower legal space than compounding unapproved peptides.

503A Individual Compounding Pharmacies

Under 21 U.S.C. § 503A, a state-licensed 503A pharmacy may compound a copy of an approved drug only when there is a "demonstrated patient need" that the commercial product cannot meet, for example, a documented allergy to an excipient in Egrifta SV, or a required dose form not commercially available. Routine price-shopping or convenience does not satisfy the 503A standard. A compounded version produced without a patient-specific medical necessity rationale is not legal under federal law even when the underlying molecule is approved [3].

503B Outsourcing Facilities

503B outsourcing facilities may compound drugs on the FDA's "drug shortage" list or drugs not otherwise commercially available in the needed form. Egrifta SV is not currently on the FDA drug shortage list as of mid-2025. Accordingly, routine 503B compounding of tesamorelin for general sale is not straightforwardly permitted, and Tennessee patients and prescribers should verify current shortage status before relying on a compounded source [3].

FDA Bulk Drug Substances List

The FDA maintains a list of bulk drug substances that may be used in compounding under specific conditions. Tesamorelin's status on this list can change; prescribers and pharmacists should check the FDA bulks list page before finalizing a compounding order. If tesamorelin is not listed as an approved bulk substance, 503A compounding using raw API (rather than repackaging the approved product) may not be compliant.

How to Get a Legal Egrifta Prescription in Tennessee: Step by Step

Getting tesamorelin legally in Tennessee follows a straightforward clinical pathway when a patient has a qualifying condition.

Step 1. Confirm the Diagnosis

The FDA-approved indication is excess abdominal fat in HIV-infected adults with lipodystrophy. A physician will review HIV treatment history, antiretroviral regimen, waist circumference, and ideally a quantitative VAT measurement. The HIV Medicine Association guidelines on metabolic complications provide clinical criteria that physicians use to determine whether VAT reduction therapy is appropriate [4].

Step 2. Choose a Prescriber

Options in Tennessee include:

• HIV/infectious disease specialists at academic medical centers (Vanderbilt University Medical Center, University of Tennessee Health Science Center)
• Endocrinologists with HIV metabolic complication experience
• Telehealth physicians licensed in Tennessee through the Interstate Medical Licensure Compact

The prescriber must hold an active Tennessee license or a compact privilege. The Tennessee Board of Medical Examiners license verification tool lets patients confirm a provider's status in about two minutes.

Step 3. Schedule a Telehealth or In-Person Consultation

A complete consultation documents current antiretroviral therapy, VAT measurement or waist circumference, fasting glucose, HbA1c, IGF-1, and body-image quality-of-life assessment. This documentation is required both for insurance prior authorization and to satisfy the standard of care under Tennessee's medical practice act.

Step 4. Obtain the Prescription and Fill It

With a valid prescription, a Tennessee patient may fill Egrifta SV at:

• Any Tennessee-licensed retail pharmacy that stocks or can order the product
• A specialty pharmacy (Egrifta SV typically requires cold-chain handling and is often dispensed through specialty channels)
• A 503A compounding pharmacy, only when medical necessity for a compounded version is documented

The manufacturer, Theratechnologies, operates a patient-support program. Their EGRIFTA SV patient assistance information outlines copay cards and free-drug programs for qualifying patients.

Step 5. Monitor and Reassess at 26 Weeks

Per the FDA-approved labeling, the treating physician should reassess VAT reduction at week 26. IGF-1 levels are checked at 1 to 3 months after initiation and periodically thereafter. If IGF-1 exceeds the upper limit of normal for age, the dose is reduced or therapy is stopped [2].

Insurance Coverage and Cost Considerations in Tennessee

Egrifta SV is a specialty biologic with a high list price. Coverage varies by payer.

Tennessee Medicaid (TennCare)

TennCare covers Egrifta SV for enrolled HIV-positive beneficiaries who meet the approved indication. Prior authorization is required. The prescriber must submit documentation of HIV diagnosis, current antiretroviral use, and quantified VAT excess. The TennCare preferred drug list is updated quarterly; verify current PA criteria before initiating therapy.

Commercial Insurance

Most commercial plans in Tennessee treat Egrifta SV as a specialty-tier drug. Prior authorization criteria typically mirror the FDA indication. Some plans require a step through dietary and exercise counseling documentation first. The FDA-approved indication language is the strongest supporting text a prescriber can include in a PA letter.

Ryan White Program

HIV-positive patients who do not qualify for Medicaid or cannot afford commercial copays may access Egrifta SV through the Ryan White HIV/AIDS Program. Tennessee's Ryan White Part B program, administered through the Tennessee Department of Health, includes an AIDS Drug Assistance Program (ADAP) formulary that has historically covered tesamorelin for qualifying patients [5].

Safety Profile and Contraindications Tennessee Prescribers Assess

A physician in Tennessee will screen for the following before prescribing, consistent with the FDA label and clinical practice guidelines.

Contraindications

The prescribing information lists active malignancy, disruption of the hypothalamic-pituitary axis (including pituitary tumor or prior pituitary surgery), and pregnancy as absolute contraindications. Patients receiving glucocorticoid replacement for hypoadrenalism may need dose adjustment because GH secretion suppresses cortisol feedback [2].

Drug Interactions with Antiretrovirals

Some protease inhibitors alter GH metabolism. Ritonavir and ritonavir-boosted regimens have been associated with metabolic changes that can complicate VAT management. The treating HIV specialist and prescribing physician should review the full antiretroviral regimen against the FDA drug interaction guidance before initiating tesamorelin [2].

Glucose and HbA1c Monitoring Protocol

GH elevations reduce insulin sensitivity. In the LIPO-010 and LIPO-011 trials, new-onset impaired glucose tolerance occurred in approximately 4.7% of tesamorelin-treated patients versus 2.0% in the placebo arm [1]. The American Diabetes Association's Standards of Medical Care in Diabetes recommends HbA1c monitoring every 3 months for patients with new metabolic risk factors, a reasonable benchmark for tesamorelin-treated patients with baseline prediabetes [6].

What Tesamorelin Is Not: Distinguishing It from Unapproved Peptides

Several peptides sold online occupy a legally ambiguous space, sometimes labeled "for research use only" to sidestep FDA enforcement. Tesamorelin is not in that category. It has an NDA number, a labeled indication, a branded product with cold-chain distribution, and FDA-required post-marketing safety reporting. Comparing it to BPC-157, ipamorelin, or CJC-1295 is a category error; those compounds lack FDA approval for any human indication as of July 2025 [7].

Patients who have been offered "tesamorelin" from an online peptide vendor without a prescription should be aware that the FDA's guidance on unapproved peptide products specifically identifies unlicensed peptide products as presenting unknown purity and potency risks. A product arriving in an unmarked vial with no lot number is not Egrifta SV regardless of what the label says.